

**From:** Mayer, Kristen /US <Kristen.Mayer@sanofi.com>  
**Sent:** Tuesday, January 07, 2020 12:18 PM  
**To:** Smith, Michael (CBER) <Michael.Smith2@fda.hhs.gov>  
**Cc:** Temenak, Joseph <Joseph.Temenak@fda.hhs.gov>; Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Sharma, Nikunj <Nikunj.Sharma@fda.hhs.gov>  
**Subject:** STN 125701.0: Late Cycle meeting

Hi Mike,

I have spoken with the team and Sanofi proposes to cancel the meeting today. The agenda items were clear. I will email you later with updates on the outstanding IR responses.

Best regards,  
Kristen

---

**From:** Smith, Michael (CBER)  
**Sent:** Tuesday, January 07, 2020 11:47 AM  
**To:** Mayer, Kristen /US <Kristen.Mayer@sanofi.com>  
**Cc:** Temenak, Joseph <Joseph.Temenak@fda.hhs.gov>; Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Sharma, Nikunj <Nikunj.Sharma@fda.hhs.gov>  
**Subject:** STN 125701.0: Late Cycle meeting

Kristen,

We have recently been informed that all employees must depart no later than 1:00 PM due to the impending bad weather in the DC area, at which time the federal offices are closed. As you know, 1:00 PM is also the start time for the Late Cycle Meeting. Please let us know if Sanofi would still like to hold the teleconference or is Sanofi would prefer to cancel this meeting (this is the review team's preference). As an alternate, less preferable option, if Sanofi would like to still hold this teleconference we would respectfully request to move the start time to 2:00 PM so the review team members, supervisors and management could potentially have time to drive home so they could then call into the teleconference. Please reply to all on this e-mail as soon as possible.

Thank you for your understanding and I am sorry for this inconvenience.

Mike

**Mike Smith, Ph.D.**  
**Captain, USPHS**

**Senior Regulatory Review Officer**  
**Food and Drug Administration**  
**Center for Biologics Evaluation & Research**  
**Office of Vaccines Research & Review**  
**Division of Vaccines and Related Products Applications**  
Tel: 301-796-2640  
[michael.smith2@fda.hhs.gov](mailto:michael.smith2@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.